Drug Trial Radar · NCT07929051
A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Mar 4, 2027
Primary completion
Jul 3, 2028
Study completion Jul 3, 2028
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with advanced cancer who received obrixtamig (BI 764532) in one of several previous studies and benefited from treatment. The goal of this study is to find out how well participants who received obrixtamig in a previous study tolerate obrixtamig. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Participants in this study continue receiving obrixtamig and any other study or standard of care anti-cancer medicines they received in their previous study at the same doses and following the same treatment schedule. Treatments are given in 3-week cycles as infusions into a vein. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. During the visits, study doctors check participants' health and take note of any unwanted effects.
Conditions
- Advanced Cancer
Interventions
ObrixtamigBiological
Obrixtamig
EzabenlimabBiological
Ezabenlimab
AtezolizumabBiological
Atezolizumab
TopotecanDrug
Topotecan
TocilizumabBiological
Tocilizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment-emergent adverse events ( AEs) during the on-treatment period.Time frame: Up to 36 months
Locations
15 sites in 6 countries. Site status is shown where the registry gives one.
Universitair Ziekenhuis Gent
Ghent, Belgium
INS Bergonie
Bordeaux, France
Hopital Louis Pradel
Bron, France
INS Curie
Paris, France
HOP Civil
Strasbourg, France
Institut Gustave Roussy
Villejuif, France
Technische Universität Dresden
Dresden, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Universitätsklinikum Würzburg AÖR
Würzburg, Germany
Saitama Medical University International Medical Center
Saitama, Hidaka, Japan
National Cancer Center Hospital
Tokyo, Chuo-ku, Japan
Medical University Gdansk
Gdansk, Poland
Polish Mother's Memorial Hospital - Research Institute
Lodz, Poland
Hospital Universitario Ramon Y Cajal
Madrid, Spain
Fundación Jiménez Díaz
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.